Earnings ·
Profound Medical anticipates Q3 revenue of $9.8M-$10.0M, exceeding consensus by ~45%
PROFProfound Medical Corp.
Profound Medical Corp. issued preliminary unaudited financial results for the third quarter ended September 30, 2026, anticipating total revenue between $9.8 million and $10.0 million. This range represents approximately 85% to 89% year-over-year growth compared to $5.3 million in Q3 2025 and roughly 292% to 300% sequential growth from $2.5 million in Q2 2026. The expected revenue exceeds the Bloomberg mean analyst consensus of $6.78 million by approximately 45% to 47%. Gross margin is also projected to exceed 70%. Full financial results will be reported after market close on November 5, 2026. Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures for prostate care and other conditions.